Retatrutide: human research and US status
A selected clinical study, its limitations and a dated FDA status check.
Sources checked October 20, 2026 · US context · Human editorial and scientific review pending
The short answer
Retatrutide has published human trial evidence. That does not make an online vial an approved medicine: FDA’s current communication says retatrutide is not a component of an FDA-approved drug.[1][2]
What has been studied?
A 2023 double-blind randomized placebo-controlled phase 2 trial enrolled 338 adults and followed treatment for 48 weeks. It reported weight reduction. This brief covers that selected study, not every subsequent trial.[1]
What about adverse effects?
The abstract reports mostly mild-to-moderate gastrointestinal adverse events and dose-dependent heart-rate increases. Trial supervision, participants and study material limit what can be inferred about other settings or products.[1]
What does the regulatory source say?
FDA states that retatrutide cannot be used in compounding under federal law. This is a dated US status check, not a worldwide regulatory assessment.[2]
Clinical evidence, authorization and the contents of a particular vial are three different questions. This brief offers no product recommendation or dosing protocol.
References and access limitsStudy design, commercial context and what was inspected
- Human clinical trial
Jastreboff AM, Kaplan LM, Frías JP, et al. 2023. New England Journal of Medicine 389:514–526.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 TrialEvidence and limitations for reference 1
- What was studied
- Randomized double-blind placebo-controlled phase 2 trial; 338 adults, 48 weeks.
- What was reported
- Weight reduction was reported; gastrointestinal adverse events and heart-rate increases were also reported.
- What this supports here
- Human trial findings for the study intervention and population.
- What it cannot establish
- Not a full current trial inventory, approval decision, long-term safety guarantee or authentication of online products.
- Commercial context and disclosures
- Funded by Eli Lilly, as stated in the abstract.
- What we inspected
- PubMed abstract and metadata inspected. Publisher full text unavailable; detailed protocols not reviewed.
- Regulatory guidanceFDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
Evidence and limitations for reference 2
- What this supports here
- The US regulator’s stated distinction or risk communication at the inspection date.
- What it cannot establish
- Not a new clinical trial or a complete literature review. Regulatory statements have a jurisdiction, date and specific scope; absence of established safety is not proof of a particular injury.
- Commercial context and disclosures
- US government regulator; not a retailer.
- What we inspected
- Public source text inspected; underlying clinical dossiers not independently reanalysed.